About quigley - PRPH
ProPhase Labs, Inc. is a medical science and technology company, which engages in the research, development, manufacture, distribution, marketing, and sale of over-the-counter consumer healthcare products and dietary supplements. It operates through the Diagnostic Services and Consumer Products segment. The Diagnostic Services segment includes COVID-19 and other diagnostic testing services. The Consumer Products segment consists of the manufacturing, retail customers, and personal genomics products and services. The company was founded by Guy J. Quigley and Charles A. Phillips in July 1989 and is headquartered in Uniondale, NY.
PRPH At a Glance
ProPhase Labs, Inc.
626 RXR Plaza
Uniondale, New York 11556
| Phone | 1-215-345-0919 | Revenue | 4.35M | |
| Industry | Pharmaceuticals: Other | Net Income | -23,489,000.00 | |
| Sector | Health Technology | Employees | 19 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
PRPH Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 0.874 |
| Price to Book Ratio | 1.144 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -1.06 |
| Enterprise Value to Sales | 2.837 |
| Total Debt to Enterprise Value | 0.699 |
PRPH Efficiency
| Revenue/Employee | 228,684.211 |
| Income Per Employee | -1,236,263.158 |
| Receivables Turnover | 2.829 |
| Total Asset Turnover | 0.071 |
PRPH Liquidity
| Current Ratio | 0.059 |
| Quick Ratio | 0.058 |
| Cash Ratio | 0.002 |
PRPH Profitability
| Gross Margin | -84.58 |
| Operating Margin | -384.12 |
| Pretax Margin | -538.251 |
| Net Margin | -540.598 |
| Return on Assets | -38.006 |
| Return on Equity | -430.66 |
| Return on Total Capital | -192.867 |
| Return on Invested Capital | -158.529 |
PRPH Capital Structure
| Total Debt to Total Equity | 245.667 |
| Total Debt to Total Capital | 71.07 |
| Total Debt to Total Assets | 14.394 |
| Long-Term Debt to Equity | 18.216 |
| Long-Term Debt to Total Capital | 5.27 |